Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

Cheng Cheng; LingShu Wang; Jason G. D. Gall; Martha Nason; Richard M. Schwartz; M. Juliana McElrath; Steven C. DeRosa; John Hural; Lawrence Corey; Susan P. Buchbinder; Gary J. Nabel

doi:10.1371/journal.pone.0033969

Loading metrics

Open Access

Peer-reviewed

Research Article

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

Cheng Cheng,

Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Insititutes of Health, Bethesda, Maryland, United States of America
⨯
LingShu Wang,

Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Insititutes of Health, Bethesda, Maryland, United States of America
⨯
Jason G. D. Gall,

Affiliation GenVec, Inc., Gaithersburg, Maryland, United States of America
⨯
Martha Nason,

Affiliation Biostatistics Research Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Richard M. Schwartz,

Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Insititutes of Health, Bethesda, Maryland, United States of America
⨯
M. Juliana McElrath,

Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, HIV Vaccine Trials Network, Seattle, Washington, United States of America
⨯
Steven C. DeRosa,

Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, HIV Vaccine Trials Network, Seattle, Washington, United States of America
⨯
John Hural,

Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, HIV Vaccine Trials Network, Seattle, Washington, United States of America
⨯
Lawrence Corey,

Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, HIV Vaccine Trials Network, Seattle, Washington, United States of America
⨯
Susan P. Buchbinder,

Affiliations HIV Vaccine Trials Network, Seattle, Washington, United States of America, HIV Research Section, San Francisco Department of Public Health, San Francisco, California, United States of America
⨯
Gary J. Nabel

* E-mail: gnabel@nih.gov

Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Insititutes of Health, Bethesda, Maryland, United States of America
⨯

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

Cheng Cheng,
LingShu Wang,
Jason G. D. Gall,
Martha Nason,
Richard M. Schwartz,
M. Juliana McElrath,
Steven C. DeRosa,
John Hural,
Lawrence Corey,
Susan P. Buchbinder

Published: April 4, 2012
https://doi.org/10.1371/journal.pone.0033969

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
Viral packaging
Is the Subject Area "Viral packaging" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
HIV infections
Is the Subject Area "HIV infections" applicable to this article?

Thanks for your feedback.
Viral vaccines
Is the Subject Area "Viral vaccines" applicable to this article?

Thanks for your feedback.